Compare Pfizer Inc (PFE) vs Tapestry, Inc. (TPR) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

TPR trades at $142.16, up 0.49% today, with a neutral technical signal but strong fundamental momentum after three consecutive quarterly earnings beats. The stock carries high valuation ratios, including a P/E of 43.02, but demonstrates robust profitability with a 76.18% gross margin and 55.74% ROE. Recent corporate news includes the appointment of Jonathan Saunders as Kate Spade's Executive Creative Director, signaling brand revitalization efforts.

Outlook remains positive with a consensus price target of $183.88, implying 29% upside, supported by 75.6% analyst buy ratings. Key risks include elevated debt levels and margin compression from 2024's 12.23% to 2025's 2.61% net income margin. Investors should weigh strong brand positioning against valuation sensitivity and cyclical retail exposure.